Lucence cancer screening is a multi-cancer early detection test that screens up to 50 cancers with a single blood draw. Developed by a team of oncologists and researchers in Singapore, Lucence has gained worldwide recognition, partnering with globally acclaimed laboratory testing healthcare organisations, including Mayo Clinic Laboratories and Agilus Diagnostics.
How is Lucence Cancer Screening Different from Tumour Markers?
Traditional tumour markers test for certain proteins found in the blood that may be produced by cancer cells. Common proteins tested in tumour markers include PSA (a protein used to screen prostate cancer), CA-125 (ovarian cancer) and CEA (colorectal cancer).
However, these proteins are not exclusively produced only when one has cancer. Sometimes, these protein levels can be temporarily elevated and can be produced by normal cells when there are hormonal changes, infections or inflammation in the body.
Tumour markers often lack specificity (ability to identify true negatives) and sensitivity (ability to identify true positives), and it is not uncommon for tumour marker test to produce false-positive or false negative results. For example, PSA tumour marker that is used in prostate cancer screening has a specificity of approximately 60% and sensitivity of 72%, reflecting limited precision in detecting prostate cancer as well as a high false positive rate.
- False negative
A false negative result refers to when an individual has cancer but their tumour marker reads within the normal range. This happens because early-stage cancers or certain tumours sometimes do not secrete high enough protein levels to be picked up in a tumour marker blood test.
- False positive
A false positive result refers to when an individual’s tumour marker test shows elevated levels of proteins when the individual does not actually have cancer. This happens because the proteins are not exclusively produced by cancer cells and can be elevated due to various different factors, such as inflammation, hormonal shifts or infections in the body.
Unlike traditional tumour marker tests that measure protein levels, Lucence tests for ctDNA present in the blood, that are shed by malignant tumours. The test offers a high specificity (measure of how well a test can identify true negatives) of 99% and sensitivity (measure of how well a test can identify true positives) of 81%.
Lucence Screening Plans
LucenceINSIGHT 50: Nasopharyngeal (EBV+) cancer, Oropharyngeal cancer, Laryngeal cancer, Salivary gland cancer, Non-hodgkin lymphoma cancer, Hairy cell leukemia, Breast cancer, Lung cancer, Lung neuroendocrine tumour, Liver cancer, Biliary tract cancer, Kidney cancer, Adult Wilms tumour, Small intestine cancer, Cervical cancer, Endometrial cancer, Ovary cancer, Ovarian germ cell and stromal tumours, Vulvar cancer, Soft tissue cancer, Eye cancer, Esophageal cancer, Thyroid cancer, Acute myeloid leukemia, Mast cell tumour, Myeloproliferative neoplasm myeloma, Bone cancer, Stomach cancer, Stomach neuroendocrine tumour, Gastrointestinal stromal tumour, Adrenal gland cancer, Pancreatic cancer, Colorectal neuroendocrine tumour, Bladder cancer, Penile cancer, Prostate cancer, Testis cancer, Melanoma
LucenceINSIGHT 12 For Women: Nasopharyngeal (EBV+) cancer, Thyroid cancer, Breast cancer, Lung Cancer, Liver cancer, Stomach cancer, Pancreatic cancer, Gastrointestinal stromal tumour, Colorectal cancer, Ovarian cancer, Cervical cancer, Endometrial cancer
LucenceINSIGHT 12 For Men: Nasopharyngeal (EBV+) cancer, Esophageal cancer, Thyroid cancer, Lung Cancer, Liver cancer, Stomach cancer, Pancreatic cancer, Kidney cancer, Gastrointestinal stromal tumour, Colorectal cancer, Bladder cancer, Prostate cancer
LucenceINSIGHT 7 for Women: Thyroid cancer, Breast cancer, Lung cancer, Liver cancer, Pancreatic cancer, Colorectal cancer, Ovarian cancer
LucenceINSIGHT 5 Unisex: Thyroid cancer, Lung cancer, Liver cancer, Pancreatic cancer, Colorectal cancer
If you are considering preventive screening and would like to find out if Lucence is suitable for you, reach out to us today to schedule a consultation.
